• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Slattery Joseph P

    11/7/25 5:15:40 PM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IMA alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    SLATTERY JOSEPH P

    (Last) (First) (Middle)
    C/O IMAGENEBIO, INC.
    2526 HIGH BLUFF DRIVE

    (Street)
    SAN DIEGO CA 92130

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    11/01/2025
    3. Issuer Name and Ticker or Trading Symbol
    ImageneBio, Inc. [ IMA ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    Exhibit 24 - Power of Attorney.
    No securities are beneficially owned.
    /s/ Erin Butler, Attorney-in-Fact 11/07/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $IMA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IMA

    DatePrice TargetRatingAnalyst
    11/25/2025$2.00Underperform
    Wedbush
    10/24/2025$30.00Outperform
    Leerink Partners
    More analyst ratings

    $IMA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wedbush resumed coverage on ImageneBio with a new price target

    Wedbush resumed coverage of ImageneBio with a rating of Underperform and set a new price target of $2.00

    11/25/25 8:27:54 AM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Leerink Partners initiated coverage on ImageneBio with a new price target

    Leerink Partners initiated coverage of ImageneBio with a rating of Outperform and set a new price target of $30.00

    10/24/25 9:00:36 AM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Principal Accounting Officer Butler Erin was granted 22,500 shares, increasing direct ownership by 737% to 25,551 units (SEC Form 4)

    4 - ImageneBio, Inc. (0001835579) (Issuer)

    1/2/26 9:15:55 PM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Slattery Joseph P bought $95,840 worth of shares (16,000 units at $5.99) (SEC Form 4)

    4 - ImageneBio, Inc. (0001835579) (Issuer)

    12/29/25 4:46:28 PM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Wang Jonathan Jian

    4 - ImageneBio, Inc. (0001835579) (Issuer)

    12/22/25 5:15:33 PM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMA
    SEC Filings

    View All

    SEC Form 424B3 filed by ImageneBio Inc.

    424B3 - ImageneBio, Inc. (0001835579) (Filer)

    12/18/25 4:06:55 PM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 8-K filed by ImageneBio Inc.

    8-K - ImageneBio, Inc. (0001835579) (Filer)

    12/18/25 4:05:08 PM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ImageneBio Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - ImageneBio, Inc. (0001835579) (Filer)

    11/19/25 7:50:18 AM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

    Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership Will build and lead Imagene's clinical organization and drive completion of the Phase 2b ADAPTIVE trial in atopic dermatitis Will expand Phase 2b trial footprint with planned international sites including in the UK and Europe SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA, "Imagene, " or the "Company")), today announced the appointment of Dr. Ben Porter-Brown, a seasoned autoimmune and inflammatory drug developer with experience in the OX40 receptor-ligand (OX40-OX40L) inhibition field, as its Chief Medical Officer. He will be fo

    2/10/26 7:00:00 AM ET
    $IMA
    $MLTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team

    $142.6 million cash and cash equivalents and marketable securities as of September 30, 2025  Protocol amendment for ongoing Phase 2b ADAPTIVE study of IMG-007 in atopic dermatitis (AD) announced to optimize study design in alignment with IMG-007's unique molecular attributes; strong patient enrollment continues Novel alopecia areata data including biomarkers from Phase 1b/2a study to be presented at upcoming Inflammatory Skin Disease Summit (ISDS) Strengthened leadership team and board with addition of Dr. Kristin Yarema as Chief Executive Officer, Dr. Kurinji Pandiyan as Chief Strategy and Operations Officer, Dr. Renuka Sivendran as Chief Technical Officer, and Joe Slattery as an indepe

    11/12/25 7:15:00 AM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ImageneBio to Participate in Fourth Quarter 2025 Investor Conferences

    SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA, "Imagene, " "Company")), a clinical-stage biotechnology company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases, including IMG-007, an anti-OX40 monoclonal antibody with multiple differentiating features, today announced management participation in fourth quarter investor conferences. 2025 Stifel Healthcare ConferenceFireside Chat: Thursday, November 13, 9:20am ESTNew York, NY Piper Sander 37th Annual Healthcare ConferenceFireside Chat: Thursday, December 4, 10:00am ESTNew York, NY To access the live webcasts or subsequent archived recordings of the presentation and f

    11/6/25 8:30:00 AM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Slattery Joseph P bought $95,840 worth of shares (16,000 units at $5.99) (SEC Form 4)

    4 - ImageneBio, Inc. (0001835579) (Issuer)

    12/29/25 4:46:28 PM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMA
    Leadership Updates

    Live Leadership Updates

    View All

    ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

    Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership Will build and lead Imagene's clinical organization and drive completion of the Phase 2b ADAPTIVE trial in atopic dermatitis Will expand Phase 2b trial footprint with planned international sites including in the UK and Europe SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA, "Imagene, " or the "Company")), today announced the appointment of Dr. Ben Porter-Brown, a seasoned autoimmune and inflammatory drug developer with experience in the OX40 receptor-ligand (OX40-OX40L) inhibition field, as its Chief Medical Officer. He will be fo

    2/10/26 7:00:00 AM ET
    $IMA
    $MLTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations